Attention Investors in Allarity Therapeutics
The Law Offices of Howard G. Smith would like to inform investors about an important upcoming deadline related to Allarity Therapeutics, Inc. Mark your calendars for November 12, which is the last day to file a lead plaintiff motion in the ongoing class action lawsuit. This case concerns individuals who purchased securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) within a specific timeframe.
Overview of the Class Action Lawsuit
This class action complaint covers the period from May 17, 2022, to July 19, 2024. During this span, allegations emerged regarding false statements made by the company's management, raising issues about the company's transparency and accountability. The Law Offices of Howard G. Smith urge investors who think they've experienced losses to get in touch and explore their options related to this legal situation.
Key Events Leading to Legal Action
Several alarming disclosures from Allarity have caught investors' attention. For example, on February 6, 2023, the company disclosed that it had received a document request from the SEC and was under investigation for possible violations of federal securities laws. Following this news, Allarity's stock dropped by 3.8%, closing at $0.228 per share.
Recent Developments Impacting Shareholders
On December 11, 2023, there was a critical leadership change as the CEO was terminated, which raised more concerns among investors. This announcement led to a 13.4% decline in the stock price, bringing it down to $0.486 per share. Furthermore, on July 22, 2024, the company faced another challenge when it received a Wells Notice from the SEC related to previous disclosures about its FDA applications for Dovitinib, causing a 2.4% drop in stock value to $0.164 per share that same day.
Legal Implications for Allarity Investors
Investors who bought Allarity securities during the identified class period might have legal grounds for seeking recourse. The lawsuit states that throughout this period, the company’s leadership allegedly made false and misleading claims about the Dovitinib NDA and its chances of approval. Specifically, they are accused of exaggerating the likelihood of regulatory approval while hiding potential legal and reputational risks associated with their actions.
Your Options as a Potential Class Member
If you purchased or obtained Allarity securities during the mentioned class period, you have until November 12 to inform the court if you want to be appointed as the lead plaintiff. While it's essential to keep this date in mind, you are not required to act immediately but may consider consulting with legal counsel.
Taking Action: Contact Information
For investors seeking advice or more details about their rights, the Law Offices of Howard G. Smith are available to assist. You can reach them by calling (215) 638-4847 or by sending an email. They are ready to help with any questions you may have regarding your interests in this legal matter.
Frequently Asked Questions
What is the deadline for filing a lead plaintiff motion?
The deadline to file a lead plaintiff motion in the class action lawsuit against Allarity Therapeutics, Inc. is November 12.
What time frame does the class action cover?
The class period for the lawsuit spans from May 17, 2022, to July 19, 2024.
What are the main allegations in the lawsuit?
The lawsuit alleges that Allarity's leadership made misleading statements regarding the Dovitinib NDA and its business prospects, failing to disclose material adverse facts.
How can I contact the law firm handling the case?
You can reach the Law Offices of Howard G. Smith at (215) 638-4847 for more information or inquiries.
What should I do if I have questions about my rights?
If you have questions regarding your rights or the class action, contacting a legal professional or the law firm can provide you with the guidance you need.
